{"id":11386210,"date":"2025-10-14T20:13:51","date_gmt":"2025-10-14T17:13:51","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&#038;p=11386210"},"modified":"2026-07-17T18:48:23","modified_gmt":"2026-07-17T15:48:23","slug":"votrient-400-mg","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/votrient-400-mg\/","title":{"rendered":"Votrient 400mg (Pazopanib) Tablets for Kidney and Soft Tissue Cancer"},"content":{"rendered":"<div dir=\"ltr\" style=\"text-align: left\">\n<h2 id=\"votrient-400\">Votrient 400mg (Pazopanib) \u2013 Complete Medical Guide for Kidney Cancer &amp; Soft Tissue Sarcoma<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 16px;border-radius: 6px;margin: 12px 0\"><strong>&#x26a0;&#xfe0f; Critical Medical Warning \u2014 Prescription Oncology Medication:<\/strong><br \/>\nVotrient (Pazopanib) is a targeted oncology therapy (TKI) requiring a prescription exclusively from a specialist oncologist. Its significant risk profile demands continuous monitoring of liver function, blood pressure, and cardiac rhythm. <strong>Prescription required from a specialist oncologist. Must not be used outside an approved medical protocol under any circumstances.<\/strong><\/div>\n<div style=\"background: #f0f7ff;border-left: 4px solid #1a73e8;padding: 16px;border-radius: 6px;margin-bottom: 16px\"><strong>Quick Answer:<\/strong> Votrient 400mg (Pazopanib) by GSK is a targeted therapy (TKI \u2014 Tyrosine Kinase Inhibitor) used for advanced Renal Cell Carcinoma (RCC) and advanced Soft Tissue Sarcoma (STS). Works by inhibiting VEGFR, PDGFR, and c-KIT receptors to block tumour blood vessel formation and growth signalling. <strong>Prescription-only oncology medication<\/strong> requiring continuous specialist monitoring.<\/div>\n<div style=\"max-width: 560px;margin: 12px 0;font-family: system-ui;direction: ltr;text-align: left\">\n<table style=\"width: 100%;border-collapse: separate;border-spacing: 0;overflow: hidden;border: 1px solid #e5e7eb;border-radius: 12px\">\n<tbody>\n<tr>\n<th style=\"width: 42%;text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Brand Name<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Votrient<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Active Ingredient<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Pazopanib Hydrochloride 400mg<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Manufacturer<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">GlaxoSmithKline (GSK) \/ Novartis<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Drug Class<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Tyrosine Kinase Inhibitor (TKI) \u2014 Anti-VEGF Targeted Therapy<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Quantity<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">30 tablets<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Dosage Form<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Film-coated oral tablet<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Primary Indications<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Advanced Renal Cell Carcinoma (RCC) \u2014 Advanced Soft Tissue Sarcoma (STS)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;font-weight: bold;color: #111;border-top: 1px solid #eee\">Prescription Status<\/th>\n<td style=\"padding: 12px 14px;color: #111\"><strong>Prescription required \u2014 specialist oncologist only<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div style=\"max-width: 560px;margin: 12px 0;padding: 14px;background: #f9f9f9;border: 1px solid #e5e7eb;border-radius: 12px;color: #111;line-height: 1.6\">Votrient 400mg Pazopanib by GSK \u2014 prescription TKI targeted therapy for advanced kidney cancer and soft tissue sarcoma. Must be taken on an empty stomach. Requires specialist oncologist prescription and continuous monitoring of liver function, blood pressure, and ECG.<\/div>\n<h2>Table of Contents<\/h2>\n<ul>\n<li><a href=\"#intro\">Introduction<\/a><\/li>\n<li><a href=\"#what-is\">What Is Votrient (Pazopanib)?<\/a><\/li>\n<li><a href=\"#mechanism\">Mechanism of Action<\/a><\/li>\n<li><a href=\"#indications\">Approved Medical Indications<\/a><\/li>\n<li><a href=\"#dosage\">Dosage &amp; Administration<\/a><\/li>\n<li><a href=\"#warnings\">Critical Medical Warnings<\/a><\/li>\n<li><a href=\"#side-effects\">Side Effects<\/a><\/li>\n<li><a href=\"#use-cases\">Clinical Use Cases<\/a><\/li>\n<li><a href=\"#avoid\">Who Should Avoid It?<\/a><\/li>\n<li><a href=\"#common-questions\">Common Questions<\/a><\/li>\n<li><a href=\"#timeline\">Treatment Response Timeline<\/a><\/li>\n<li><a href=\"#myths\">Myths vs Facts<\/a><\/li>\n<li><a href=\"#interactions\">Drug Interactions<\/a><\/li>\n<li><a href=\"#contraindications\">Contraindications<\/a><\/li>\n<li><a href=\"#tests\">Required Tests &amp; Monitoring<\/a><\/li>\n<li><a href=\"#lifestyle\">Lifestyle During Treatment<\/a><\/li>\n<li><a href=\"#other-meds\">Effect on Other Medications<\/a><\/li>\n<li><a href=\"#see-doctor\">When to Contact Your Doctor Immediately<\/a><\/li>\n<li><a href=\"#expert-tip\">NSL Expert Tip<\/a><\/li>\n<li><a href=\"#faq\">FAQ<\/a><\/li>\n<li><a href=\"#conclusion\">Conclusion<\/a><\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"intro\">Introduction<\/h2>\n<p>Renal Cell Carcinoma (RCC) and advanced Soft Tissue Sarcoma are among the most challenging tumours for conventional chemotherapy. The revolution of targeted therapy has transformed the oncology landscape \u2014 and Tyrosine Kinase Inhibitors (TKIs) like pazopanib represent a genuine breakthrough in these tumour types.<\/p>\n<p>Votrient (Pazopanib) is a <strong>prescription-only<\/strong> oncology medication from a specialist oncologist. It must not be used outside an approved medical protocol.<\/p>\n<hr \/>\n<h2 id=\"what-is\">What Is Votrient (Pazopanib)?<\/h2>\n<p>Votrient is the brand name for Pazopanib Hydrochloride from GSK\/Novartis. Pazopanib is a selective multi-target Tyrosine Kinase Inhibitor (TKI) that inhibits:<\/p>\n<ul>\n<li><strong>VEGFR-1, -2, -3:<\/strong> Vascular Endothelial Growth Factor receptors \u2014 blocks new tumour blood vessel formation (Angiogenesis)<\/li>\n<li><strong>PDGFR-\u03b1 and PDGFR-\u03b2:<\/strong> Platelet-Derived Growth Factor receptors<\/li>\n<li><strong>c-KIT:<\/strong> Stem Cell Factor receptor<\/li>\n<\/ul>\n<p>The result: the tumour is deprived of its blood supply and key growth signals, halting cellular proliferation and limiting spread.<\/p>\n<hr \/>\n<h2 id=\"mechanism\">Mechanism of Action \u2014 How Pazopanib Stops Tumour Growth<\/h2>\n<ul>\n<li><strong>Angiogenesis inhibition:<\/strong> Tumours require building new blood vessel networks to grow. VEGFR is the primary driver of this process \u2014 pazopanib silences it<\/li>\n<li><strong>Tumour cell proliferation inhibition:<\/strong> PDGFR and c-KIT transmit growth signals to cancer cells \u2014 pazopanib cuts these signals<\/li>\n<li><strong>Tumour microenvironment disruption:<\/strong> Narrows the favourable conditions for tumour growth and spread<\/li>\n<\/ul>\n<p>This makes it particularly effective in highly vascular tumours such as Clear Cell Renal Cell Carcinoma.<\/p>\n<hr \/>\n<h2 id=\"indications\">Approved Medical Indications<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 12px;border-radius: 6px\"><strong>Specialist oncologist prescription required in all cases.<\/strong><\/div>\n<ul>\n<li><strong>Advanced Renal Cell Carcinoma (RCC):<\/strong> First or second-line treatment for inoperable or metastatic kidney cancer<\/li>\n<li><strong>Advanced Soft Tissue Sarcoma (STS):<\/strong> Following prior chemotherapy \u2014 excluding specific subtypes<\/li>\n<\/ul>\n<p>Note: Votrient is not approved for cancers outside these two indications.<\/p>\n<hr \/>\n<h2 id=\"dosage\">Dosage &amp; Administration<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 16px;border-radius: 6px\"><strong>&#x26a0;&#xfe0f; Dosage is determined exclusively by the treating oncologist. The following is for reference only.<\/strong><\/div>\n<ul>\n<li>Approved dose: <strong>800mg (two 400mg tablets) once daily<\/strong><\/li>\n<li>Must be taken on an <strong>empty stomach<\/strong> \u2014 at least 1 hour before food or 2 hours after<\/li>\n<li><strong>Do not crush or break tablets<\/strong> \u2014 swallow whole<\/li>\n<li>In hepatotoxicity: dose reduction or discontinuation by physician decision<\/li>\n<li>Do not stop without consulting your oncologist even if side effects appear<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"warnings\">Critical Medical Warnings<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 16px;border-radius: 6px\"><strong>&#x1f6a8; Core safety warnings \u2014 prescription required with continuous monitoring:<\/strong><\/div>\n<ul>\n<li><strong>Severe Hepatotoxicity:<\/strong> Among the most serious adverse effects \u2014 liver function tests are mandatory before and during treatment. Fatal hepatic failure cases have been reported.<\/li>\n<li><strong>Hypertension:<\/strong> Very common \u2014 blood pressure must be controlled before starting and monitored continuously<\/li>\n<li><strong>QT Prolongation \/ Torsades de Pointes:<\/strong> Risk of cardiac arrhythmia \u2014 ECG monitoring required<\/li>\n<li><strong>Bleeding risk:<\/strong> Pazopanib&#8217;s VEGFR inhibition increases the risk of severe haemorrhage<\/li>\n<li><strong>Venous and arterial thromboembolic events<\/strong><\/li>\n<li><strong>Gastrointestinal perforation or fistula<\/strong><\/li>\n<li><strong>Hypertensive crisis<\/strong><\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"side-effects\">Side Effects<\/h2>\n<h3>Very common (&gt;20% of patients):<\/h3>\n<ul>\n<li>Diarrhoea \u2014 among the most frequent<\/li>\n<li>Hypertension<\/li>\n<li>Hair colour change (lighter or grey)<\/li>\n<li>Nausea and vomiting<\/li>\n<li>Loss of appetite and weight loss<\/li>\n<li>Fatigue and general weakness<\/li>\n<li>Elevated liver enzymes (ALT\/AST)<\/li>\n<\/ul>\n<h3>Common (10\u201320%):<\/h3>\n<ul>\n<li>Headache<\/li>\n<li>Abdominal pain<\/li>\n<li>Hoarseness of voice<\/li>\n<li>Hand-Foot Syndrome (palmar-plantar erythrodysaesthesia)<\/li>\n<li>Decreased white blood cells and platelets<\/li>\n<\/ul>\n<h3>Rare but serious:<\/h3>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 12px;border-radius: 6px\">\n<ul>\n<li>Acute liver failure<\/li>\n<li>Severe internal haemorrhage<\/li>\n<li>Pulmonary or cardiac thromboembolism<\/li>\n<li>Gastrointestinal perforation<\/li>\n<li>QT prolongation and cardiac arrhythmia<\/li>\n<\/ul>\n<\/div>\n<hr \/>\n<h2 id=\"use-cases\">Clinical Use Cases<\/h2>\n<table style=\"border-collapse: collapse;width: 100%\" border=\"1\" cellpadding=\"8\">\n<tbody>\n<tr>\n<th>Situation<\/th>\n<th>Votrient&#8217;s Role<\/th>\n<th>Note<\/th>\n<\/tr>\n<tr>\n<td>Advanced Clear Cell RCC \u2014 first line<\/td>\n<td>Established first-line treatment<\/td>\n<td>Comparable to sunitinib \u2014 similar efficacy with different tolerability profile<\/td>\n<\/tr>\n<tr>\n<td>Advanced RCC \u2014 second line<\/td>\n<td>After immunotherapy failure<\/td>\n<td>By oncologist decision<\/td>\n<\/tr>\n<tr>\n<td>Advanced Soft Tissue Sarcoma<\/td>\n<td>After prior chemotherapy failure<\/td>\n<td>Approved for specific subtypes only<\/td>\n<\/tr>\n<tr>\n<td>Other indications<\/td>\n<td>Not approved<\/td>\n<td>Must not be used outside approved indications<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"avoid\">Who Should Avoid Votrient?<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 16px;border-radius: 6px\"><strong>&#x26a0;&#xfe0f; Absolute contraindications \u2014 prescription required in all cases:<\/strong><\/div>\n<ul>\n<li><strong>Severe hepatic impairment:<\/strong> Prohibited \u2014 risk of fatal toxicity<\/li>\n<li><strong>Pregnancy:<\/strong> Prohibited \u2014 Teratogenic (causes fetal abnormalities)<\/li>\n<li><strong>Breastfeeding:<\/strong> Discontinue breastfeeding during treatment<\/li>\n<li><strong>Severe QT prolongation or uncontrolled cardiac arrhythmia<\/strong><\/li>\n<li><strong>Active acute haemorrhage<\/strong><\/li>\n<li><strong>Uncontrolled hypertension<\/strong><\/li>\n<li><strong>Known hypersensitivity to pazopanib<\/strong><\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"common-questions\">Common Questions Patients Actually Ask<\/h2>\n<h3>Why must it be taken on an empty stomach?<\/h3>\n<p>Food significantly increases pazopanib absorption, potentially raising blood levels to toxic concentrations. Fasting administration provides predictable, safer, and more effective absorption.<\/p>\n<h3>Why does hair colour change?<\/h3>\n<p>c-KIT inhibition affects melanocyte cells that produce hair pigment. Colour change (lighter or grey) is a known, non-dangerous side effect that typically reverses after treatment ends.<\/p>\n<h3>Is diarrhoea dangerous?<\/h3>\n<p>Mild to moderate diarrhoea is common and managed with medications and hydration. Severe diarrhoea (Grade 3\u20134) requires medical intervention and may necessitate dose reduction.<\/p>\n<h3>How will I know if my liver is being affected?<\/h3>\n<p>Elevated ALT\/AST on routine blood tests is the primary indicator. Symptoms to report immediately: yellowing of skin or eyes (jaundice), severe right-sided abdominal pain, dark urine.<\/p>\n<hr \/>\n<h2 id=\"timeline\">Treatment Response Timeline<\/h2>\n<table style=\"border-collapse: collapse;width: 100%\" border=\"1\" cellpadding=\"8\">\n<tbody>\n<tr>\n<th>Period<\/th>\n<th>What Happens<\/th>\n<\/tr>\n<tr>\n<td>Week 1<\/td>\n<td>Therapeutic effect begins \u2014 early side effects common (diarrhoea, nausea, fatigue)<\/td>\n<\/tr>\n<tr>\n<td>4\u20138 weeks<\/td>\n<td>First imaging response assessment \u2014 evaluating tumour response<\/td>\n<\/tr>\n<tr>\n<td>2\u20134 months<\/td>\n<td>Comprehensive assessment \u2014 Imaging per RECIST criteria<\/td>\n<\/tr>\n<tr>\n<td>Ongoing<\/td>\n<td>Regular monitoring of response and side effects throughout treatment duration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"myths\">Myths vs Facts<\/h2>\n<table style=\"border-collapse: collapse;width: 100%\" border=\"1\" cellpadding=\"8\">\n<tbody>\n<tr>\n<th>Myth<\/th>\n<th>Fact<\/th>\n<\/tr>\n<tr>\n<td>&#8220;Targeted therapy is less dangerous than chemotherapy.&#8221;<\/td>\n<td>Targeted therapy has serious but different side effects from classical chemotherapy \u2014 not less dangerous, but different in nature. Hepatotoxicity and cardiovascular risks are among its serious concerns.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;Votrient can be purchased without a prescription.&#8221;<\/td>\n<td>Legally and medically prohibited. Using it outside oncologist supervision exposes the patient to potentially fatal complications without monitoring.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;Hair colour change means the drug is harming the body.&#8221;<\/td>\n<td>Hair colour change is a known side effect of c-KIT inhibition \u2014 non-harmful and typically reverses after treatment ends.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;Votrient cures cancer.&#8221;<\/td>\n<td>Votrient controls tumour growth and improves Progression-Free Survival but is not a curative treatment in the absolute sense for most patients.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"interactions\">Drug Interactions<\/h2>\n<table style=\"border-collapse: collapse;width: 100%\" border=\"1\" cellpadding=\"8\">\n<tbody>\n<tr>\n<th>Drug \/ Substance<\/th>\n<th>Interaction<\/th>\n<th>Recommendation<\/th>\n<\/tr>\n<tr>\n<td>Strong CYP3A4 inhibitors (ketoconazole, clarithromycin)<\/td>\n<td>Raises pazopanib blood levels to dangerous concentrations<\/td>\n<td>Avoid \u2014 use weaker alternative if necessary<\/td>\n<\/tr>\n<tr>\n<td>CYP3A4 inducers (rifampicin, phenytoin, carbamazepine)<\/td>\n<td>Significantly reduces pazopanib efficacy<\/td>\n<td>Avoid \u2014 may require dose increase<\/td>\n<\/tr>\n<tr>\n<td>QT-prolonging drugs (haloperidol, amiodarone)<\/td>\n<td>Risk of acute cardiac arrhythmia<\/td>\n<td>Avoid entirely<\/td>\n<\/tr>\n<tr>\n<td>Anticoagulants (warfarin)<\/td>\n<td>Increased bleeding risk<\/td>\n<td>Monitor INR with your doctor<\/td>\n<\/tr>\n<tr>\n<td>Simvastatin<\/td>\n<td>Increased liver enzyme elevation risk<\/td>\n<td>Monitor liver function closely<\/td>\n<\/tr>\n<tr>\n<td>Proton pump inhibitors (omeprazole)<\/td>\n<td>Reduces pazopanib absorption<\/td>\n<td>Avoid \u2014 use H2 antagonists instead<\/td>\n<\/tr>\n<tr>\n<td>Grapefruit and grapefruit juice<\/td>\n<td>CYP3A4 inhibition raises drug levels<\/td>\n<td>Avoid entirely during treatment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Source: <a href=\"https:\/\/medlineplus.gov\/druginfo\/meds\/a611019.html\" target=\"_blank\" rel=\"noopener nofollow\">MedlinePlus \u2013 Pazopanib<\/a><\/p>\n<hr \/>\n<h2 id=\"contraindications\">Full Contraindications<\/h2>\n<p><strong>Prescription required in all cases:<\/strong><\/p>\n<ul>\n<li>Severe hepatic impairment \u2014 absolutely prohibited<\/li>\n<li>Pregnancy \u2014 Teratogenic<\/li>\n<li>Breastfeeding \u2014 discontinue during treatment<\/li>\n<li>Uncontrolled cardiac arrhythmia or severe QT prolongation<\/li>\n<li>Active acute haemorrhage<\/li>\n<li>Uncontrolled hypertension<\/li>\n<li>Known hypersensitivity to active ingredient<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"tests\">Required Tests &amp; Monitoring<\/h2>\n<ul>\n<li><strong>Liver function (ALT\/AST\/Bilirubin):<\/strong> Before starting and every 4 weeks for first months, then periodically<\/li>\n<li><strong>Blood pressure:<\/strong> Before starting and weekly monitoring in first months<\/li>\n<li><strong>ECG (electrocardiogram):<\/strong> Before starting and upon any cardiac symptoms<\/li>\n<li><strong>Full blood count (CBC):<\/strong> Periodic monitoring<\/li>\n<li><strong>Kidney function:<\/strong> Periodic monitoring<\/li>\n<li><strong>Imaging (CT\/MRI):<\/strong> To assess tumour response every 6\u20138 weeks<\/li>\n<li><strong>TSH (thyroid function):<\/strong> Pazopanib may affect thyroid function<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"lifestyle\">Lifestyle During Votrient Treatment<\/h2>\n<ul>\n<li><strong>Empty stomach for each dose:<\/strong> At least 1 hour before food or 2 hours after \u2014 mandatory<\/li>\n<li><strong>Avoid grapefruit entirely:<\/strong> Raises drug to dangerous levels<\/li>\n<li><strong>Good hydration:<\/strong> Reduces severity of diarrhoea and fatigue<\/li>\n<li><strong>Daily blood pressure monitoring:<\/strong> Regular home readings<\/li>\n<li><strong>Avoid herbal remedies:<\/strong> Many affect CYP3A4 enzymes<\/li>\n<li><strong>Skin protection:<\/strong> Hand-Foot Syndrome \u2014 moisturising creams and avoiding sustained pressure<\/li>\n<li><strong>Absolute contraception<\/strong> during treatment and for at least one month after<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"other-meds\">Effect of Votrient on Other Medications<\/h2>\n<ul>\n<li>Pazopanib inhibits and is metabolised via CYP3A4 \u2014 extensive interactions with many medications<\/li>\n<li>Also inhibits CYP2C8 and P-glycoprotein \u2014 inform your doctor of all medications<\/li>\n<li>Inhibits simvastatin and some statins \u2014 increases myopathy risk<\/li>\n<li>Do not start any new medication without informing your oncologist<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"see-doctor\">When to Contact Your Doctor Immediately<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 16px;border-radius: 6px\"><strong>Call your doctor or go to the nearest emergency department immediately for:<\/strong><\/p>\n<ul>\n<li>Yellowing of skin or eyes (jaundice) \u2014 hepatotoxicity<\/li>\n<li>Chest pain or irregular heartbeat<\/li>\n<li>Sudden severe headache or visual disturbances \u2014 hypertensive crisis<\/li>\n<li>Unusual bleeding (blood in stool, urine, or vomit)<\/li>\n<li>Acute shortness of breath<\/li>\n<li>Severe abdominal pain<\/li>\n<li>Severe unstoppable diarrhoea with dehydration<\/li>\n<\/ul>\n<\/div>\n<ul>\n<li>Before any surgery \u2014 stop Votrient and inform the surgeon<\/li>\n<li>If you want to stop the medication \u2014 never do so without your oncologist<\/li>\n<\/ul>\n<hr \/>\n<div style=\"background: #fff8e6;border-left: 4px solid #f5a623;padding: 16px;border-radius: 6px\">\n<h2 id=\"expert-tip\" style=\"margin-top: 0\">NSL Expert Tip<\/h2>\n<p><strong>Dr. Abdallah Fouad, Clinical Nutrition Specialist \u2014 25+ years of experience:<\/strong><\/p>\n<p>&#8220;Votrient (Pazopanib) requires a prescription and is a serious targeted oncology medication requiring continuous medical monitoring. Three things I always emphasise: First, fasting administration is mandatory \u2014 food changes its absorption profile fundamentally. Second, liver function, blood pressure, and cardiac monitoring are not optional \u2014 they are part of the treatment protocol. Third, if jaundice symptoms, chest pain, or sudden severe headache appear \u2014 go to the nearest emergency department immediately. When used correctly under oncologist supervision, this medication genuinely improves quality of life and disease outcomes in advanced kidney cancer and soft tissue sarcoma.&#8221;<\/p>\n<\/div>\n<hr \/>\n<h2 id=\"faq\">Frequently Asked Questions<\/h2>\n<h3>Is Votrient a chemotherapy drug?<\/h3>\n<p>Not in the conventional sense. Votrient is a targeted therapy (Targeted Therapy\/TKI) that acts on specific receptors rather than destroying all rapidly dividing cells like classical chemotherapy. Its side effect profile is different in nature.<\/p>\n<h3>Does it cause hair loss?<\/h3>\n<p>Complete hair loss (as seen with classical chemotherapy) is uncommon with Votrient. The more common effect is hair colour change (lighter or grey) from c-KIT inhibition \u2014 not hair loss per se.<\/p>\n<h3>Can Votrient be combined with immunotherapy?<\/h3>\n<p>This is exclusively an oncologist&#8217;s decision based on specific protocol. Some combinations are under clinical study and some are contraindicated.<\/p>\n<h3>How long is Votrient treatment continued?<\/h3>\n<p>The patient continues until disease progression or unacceptable toxicity. The physician evaluates response periodically and decides on continuation or switching treatment.<\/p>\n<h3>Where can I buy authentic Votrient in Egypt?<\/h3>\n<p>Available through No Style Like store with guaranteed authentic GSK\/Novartis sourcing and verified expiry dates. Dispensed on oncologist prescription only.<\/p>\n<hr \/>\n<h2 id=\"conclusion\">Conclusion<\/h2>\n<p>Votrient 400mg (Pazopanib) is an effective targeted therapy for advanced Renal Cell Carcinoma and advanced Soft Tissue Sarcoma \u2014 requires prescription and continuous monitoring from a specialist oncologist. Works by inhibiting VEGFR, PDGFR, and c-KIT to block tumour blood vessel formation and growth signalling.<\/p>\n<p>Correct use: on an empty stomach, with rigorous monitoring of liver function, blood pressure, and cardiac rhythm, complete avoidance of grapefruit and strong CYP3A4 inhibitors, and absolute contraception during treatment.<\/p>\n<p><strong>Related:<\/strong> <a href=\"\/?product_cat=cancer-treatment\" target=\"_blank\" rel=\"noopener\">Cancer Treatment<\/a> \u00b7 <a href=\"https:\/\/nostylelike.net\/en\/product-category\/health-symptoms\/kidney-function\/\" target=\"_blank\" rel=\"noopener\">Kidney Function<\/a><\/p>\n<p><strong>Reviewed by:<\/strong> Dr. Abdallah Fouad, Clinical Nutrition Specialist \u2014 25+ years of experience<\/p>\n<p><em><strong>Medical Disclaimer:<\/strong> Votrient is a prescription oncology medication requiring specialist oncologist supervision. Information here is educational only. Source: <a href=\"https:\/\/medlineplus.gov\/druginfo\/meds\/a611019.html\" target=\"_blank\" rel=\"noopener nofollow\">MedlinePlus \u2013 Pazopanib<\/a><\/em><\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<div style=\"max-width: 560px; margin: 12px 0; font-family: system-ui,-apple-system,Segoe UI,Roboto,Arial; direction: ltr; text-align: left;\">\n<table style=\"width: 100%; border-collapse: separate; border-spacing: 0; overflow: hidden; border: 1px solid #e5e7eb; border-radius: 12px;\">\n<tbody>\n<tr>\n<th style=\"width: 42%; text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Name<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Votrient (Pazopanib) 400mg Tablets<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Brand<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Novartis<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Strength<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">400 mg (Each tablet contains 417 mg Pazopanib Hydrochloride equivalent to 400 mg Pazopanib)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Quantity \/ Size<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">30 Film-Coated Tablets<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Form<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Film-Coated Tablets (Oral Use)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Appearance<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">White rectangular box with orange highlights, clearly labeled \u201cVotrient 400 mg\u201d, includes liver toxicity warning and unique barcode (NDC).<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Expiry Date<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Varies by batch (we supply only recent, valid batches)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Country of Origin<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Singapore<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; font-weight: bold; color: #111; border-bottom: 0; border-top: 1px solid #eee;\">Product Code<\/th>\n<td style=\"padding: 12px 14px; color: #111; border-bottom: 0; border-top: 1px solid #eee;\">NDC 0173-0804-09<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ai-optimize-6\"><!-- Short Description --><\/p>\n<div style=\"max-width: 560px; margin: 12px 0; padding: 14px; background: #f9f9f9; border: 1px solid #e5e7eb; border-radius: 12px; font-family: system-ui,-apple-system,Segoe UI,Roboto,Arial; direction: ltr; text-align: left; color: #111; line-height: 1.6;\"><strong>Votrient 400mg (Pazopanib)<\/strong> by <strong>Novartis<\/strong> is a targeted therapy designed to treat <strong>advanced kidney cancer (RCC)<\/strong> and <strong>soft tissue sarcoma (STS)<\/strong>. It works by blocking tyrosine kinases involved in tumor growth and angiogenesis. Administered orally once daily on an empty stomach, this medicine requires regular liver function monitoring due to potential hepatotoxicity. Store at room temperature (20\u201325\u00b0C) away from moisture. Always use under strict medical supervision. <strong>Order now from No Style Like.<\/strong><\/div>\n","protected":false},"featured_media":11386207,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[41585,42053],"product_tag":[38490,38486,38488,38485,38487,37715,38489,38479,38491,38492],"class_list":["post-11386210","product","type-product","status-publish","has-post-thumbnail","product_cat-cancer-medications","product_cat-kidney-function","product_tag-anti-cancer-tablets","product_tag-kidney-cancer-treatment","product_tag-novartis-oncology","product_tag-pazopanib-tablets","product_tag-soft-tissue-sarcoma","product_tag-targeted-therapy","product_tag-tyrosine-kinase-inhibitor","product_tag-votrient-400mg","product_tag-votrient-price","product_tag-votrient-uses","first","onbackorder","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11386210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/comments?post=11386210"}],"version-history":[{"count":3,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11386210\/revisions"}],"predecessor-version":[{"id":11404123,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11386210\/revisions\/11404123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media\/11386207"}],"wp:attachment":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media?parent=11386210"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_brand?post=11386210"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_cat?post=11386210"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_tag?post=11386210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}